52-Week Performance Chart

Powered by FactSet Research Systems Inc

Recent Company News

More

Powered by FactSet Research Systems Inc.

Corporate Actions/Books Closed

More
Apr 28, 2025

Kazia Therapeutics

Kazia Therapeutics Limited - Books Closed / Open Announcement
Apr 01, 2025

Kazia Therapeutics

Kazia Therapeutics Limited - Ratio Change and Reverse Split
Mar 10, 2025

Kazia Therapeutics

Kazia Therapeutics Limited - Ratio Change and Reverse Split - REVISED
Mar 06, 2025

Kazia Therapeutics

Kazia Therapeutics Limited - Ratio Change and Reverse Split

Capital Raising Events

More
DR Price Date DR Price (USD) US/Non-US/Total DRS US/Non-US/Total DR Capital Raised
Nov 30, 2023 .45 2,620,000
0
2,620,000 		1,179,000
0
1,179,000
Mar 29, 2021 13.17 303,758
0
303,758 		4,000,493
0
4,000,493
Feb 21, 2017- Change of Custodian - Country: Australia

No DR Events are available.

Data provided by Thomson Reuters

Institutional Ownership

More
TOP INSTITUTIONAL HOLDERS POSITION
Dauntless Investment Group LLC 80,617
Barclays Capital, Inc. 24,000
UBS Securities LLC 5,255
TOP MUTUAL FUND HOLDERS POSITION
Fidelity Nasdaq Composite Index Fund 196

Data provided by FactSet Research Systems Inc.

DR Details

DR Symbol KZIA
CUSIP 48669G303
DR Venue NASDAQ Stock Market
DR ISIN US48669G3039
Ratio DR:ORD 1:500
Local Exchange Not Traded
Underlying ISIN AU000000KZA9
Underlying SEDOL BD20RQ3
Country Australia
Effective Date Dec 29, 1998
Depositary BK (Sponsored)
Industry Pharma. & Biotech.
Books Open/Closed Open
Kazia Therapeutics Limited is an oncology focused drug development company. The Company is engaged in the pharmaceutical research and development. Its lead program includes Paxalisib and EVT801. Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3), which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body.

Data provided by Mergent, Inc.

Fee Type in US Dollar per ADS Deposit Agreement
Annual Depositary Service up to $0.0500
Cancellation up to $0.0500
Cash Distribution up to $0.0500
Issuance up to $0.0500
Registrar Inspection up to $0.0000
Cash Distribution(Other) up to $0.0500
Rights - Issuance up to $0.0500
Stock Dividend up to $0.0500
Transfer up to $0.0000
Cable Fee per Cancellation $17.5000

Monthly Trading Summary

More
Month Month End DR Close Price DR Trading Volume Avg Day DR Trading Volume
Jun.25 6.27 52,501,053 2,625,053
May.25 3.80 476,058 22,669
Apr.25 3.59 1,297,243 61,773

Powered by FactSet Research Systems Inc.

This information and data is provided for general informational purposes only.  Certain displayed prices may not reflect direct quotes from any market or exchange, but may instead reflect an approximation of price based on a methodology that includes a calculation that includes the price of underlying securities and foreign exchange rate selected for such purpose. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to Terms of Use

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE

Data provided by Thomson Reuters, Inc.

BNY.COM TERMS OF USE PRIVACY POLICY

© 2025 The Bank of New York Mellon Corporation. Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Quotes delayed at least 15 minutes. Market data provided by ICE Data Services. ICE Limitations.
News provided by Comtex News Network and MarketWatch. Powered and implemented by FactSet. Legal Statement.

Certain information included in this website is proprietary to Mergent, Inc. (Mergent) Copyright © 2003-2025. Reproduction of such information in any form is prohibited. Because of the possibility of human or mechanical error by Mergent's sources, Mergent or others, Mergent does not guarantee the accuracy, adequacy, completeness, timeliness or availability or for the results obtained from the use of such information. Mergent Terms of Use apply

Holdings information provided by FactSet Research Systems Inc. Copyright © 2003-2025 FactSet Research Systems Inc. All rights reserved.

Thomson Reuters Marks: The THOMSON REUTERS Kinesis Logo depicted below and THOMSON REUTERS

Redistributor shall display or print the Thomson Reuters Trademarks when Redistributor's Customers are given access to the Services.

Where Redistributor makes available on display any and all Thomson Reuters Marks attributable to the Services, Redistributor shall include the following language in the Help About section or in a general attribution page: "The THOMSON REUTERS Kinesis Logo and THOMSON REUTERS are trademarks of Thomson Reuters and its affiliated companies in the United States and other countries and used herein under license."

Additional Attribution Guidelines by Thomson Reuters: Redistributor shall display or print the following notice in the Help About section or in a general attribution page. "Copyright ©, Thomson Reuters, 1999-2025. All Rights Reserved. Use, duplication, or sale of this service, or data contained herein, except as described in the [Authorized Products name] Subscription Agreement, is strictly prohibited."

THOMSON REUTERS